UK CMA Threatens Phase 2 Probe of $25B AkzoNobel-Axalta Merger
AXTA sits 50% above its 52-week low of $24.937.
Summary
The UK Competition and Markets Authority says the AkzoNobel-Axalta merger may lessen competition within a market or markets in the UK, and it will refer the deal for an in-depth Phase 2 investigation unless the companies offer undertakings. The CMA's assessment identifies concerns on UK vehicle refinish coatings supply. AkzoNobel and Axalta plan to address the concern with the same remedy proposal as per the EU, with undertakings to divest AkzoNobel's European vehicle refinish coatings business, including the UK vehicle refinish coatings business. This is a fresh regulatory snag after the European Commission conditionally cleared the deal on November 6, which had been framed as the last major hurdle. The UK is now the remaining gating item, and a Phase 2 referral would push the timeline out by months and add divestiture risk beyond the North American Building Products sale already planned. Axalta shares sit near their 52-week high, so any sign the deal slips is a direct hit to the merger-arb spread. The companies remain confident that the merger will be completed early 2027.
At the time of this announcement, AXTA was trading at $37.38 on NYSE in the Manufacturing sector, with a market capitalization of approximately $8B. The 52-week trading range was $24.94 to $38.61. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Dow Jones Newswires.